X-25013530-GGCCGCGGCGGCCGCGGCCGCGGCT-GGCCGCGGCGGCCGCGGCCGCGGCTGCCGCGGCGGCCGCGGCCGCGGCT
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PM4PP5_Very_Strong
The NM_139058.3(ARX):c.464_465insAGCCGCGGCCGCGGCCGCCGCGGC(p.Ala148_Ala155dup) variant causes a inframe insertion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000246 in 813,857 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.0000096 ( 0 hom., 0 hem., cov: 21)
Exomes 𝑓: 0.0000014 ( 0 hom. 0 hem. )
Consequence
ARX
NM_139058.3 inframe_insertion
NM_139058.3 inframe_insertion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.378
Genes affected
ARX (HGNC:18060): (aristaless related homeobox) This gene is a homeobox-containing gene expressed during development. The expressed protein contains two conserved domains, a C-peptide (or aristaless domain) and the prd-like class homeobox domain. It is a member of the group-II aristaless-related protein family whose members are expressed primarily in the central and/or peripheral nervous system. This gene is thought to be involved in CNS development. Expansion of a polyalanine tract and other mutations in this gene cause X-linked cognitive disability and epilepsy. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_139058.3.
PP5
Variant X-25013530-G-GGCCGCGGCGGCCGCGGCCGCGGCT is Pathogenic according to our data. Variant chrX-25013530-G-GGCCGCGGCGGCCGCGGCCGCGGCT is described in ClinVar as [Pathogenic]. Clinvar id is 96455.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ARX | NM_139058.3 | c.464_465insAGCCGCGGCCGCGGCCGCCGCGGC | p.Ala148_Ala155dup | inframe_insertion | 2/5 | ENST00000379044.5 | NP_620689.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ARX | ENST00000379044.5 | c.464_465insAGCCGCGGCCGCGGCCGCCGCGGC | p.Ala148_Ala155dup | inframe_insertion | 2/5 | 1 | NM_139058.3 | ENSP00000368332 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000955 AC: 1AN: 104668Hom.: 0 Cov.: 21 AF XY: 0.00 AC XY: 0AN XY: 29916
GnomAD3 genomes
AF:
AC:
1
AN:
104668
Hom.:
Cov.:
21
AF XY:
AC XY:
0
AN XY:
29916
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000141 AC: 1AN: 709189Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 214631
GnomAD4 exome
AF:
AC:
1
AN:
709189
Hom.:
Cov.:
30
AF XY:
AC XY:
0
AN XY:
214631
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000955 AC: 1AN: 104668Hom.: 0 Cov.: 21 AF XY: 0.00 AC XY: 0AN XY: 29916
GnomAD4 genome
AF:
AC:
1
AN:
104668
Hom.:
Cov.:
21
AF XY:
AC XY:
0
AN XY:
29916
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Jun 17, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 08, 2016 | This variant is the most common pathogenic repeat allele of the second poly-alanine tract (called PA2) within exon 2 of the ARX gene. This repeat allele has been reported with various nomenclatures in multiple individuals with ARX-related diseases including intellectual disability and X-linked infantile spasm syndrome among others.1-4 References: Kato et al. Am J Hum Genet. 2007 Aug;81(2):361-6. Stromme et al. Nat Genet. 2002 Apr;30(4):441-5 Gronskov et al. Eur J Hum Genet. 2004 Sep;12(9):701-5 Marques et al. Mol Genet Genomic Med. 2015 May;3(3):203-14 - |
Pathogenic, no assertion criteria provided | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Jan 30, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 29, 2022 | Alanine repeat expansion in the second polyalanine tract of the ARX protein, extending the allele to 20 repeats; Published functional studies demonstrate a damaging effect as expansions in the second polyalanine repeat track are suggested to interfere with ARX-related regulation of KDM5C resulting in the misregulation of numerous downstream processes (Poeta et al., 2013); Not observed in unaffected adult males referred for testing at GeneDx; This variant is associated with the following publications: (PMID: 22922607, 11889467, 24528893, 26029707, 24781210, 23246292, 12874418) - |
Intellectual disability, X-linked, with or without seizures, arx-related;C3463992:Developmental and epileptic encephalopathy, 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 02, 2024 | This variant, c.441_464dup, results in the insertion of 8 amino acid(s) of the ARX protein (p.Ala148_Ala155dup), but otherwise preserves the integrity of the reading frame. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the gnomAD database. This variant has been observed in individual(s) with Partington-like syndrome, West syndrome, and/or infantile spasms (PMID: 12874418, 22922607, 24781210, 26029707). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 96455). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on ARX function (PMID: 23246292). This variant results in expansion of a poly-alanine tract in ARX. Expansions of the alanine tracts in ARX have been observed in individuals with ARX-related conditions (PMID: 11889467, 17664401, 23246292). For these reasons, this variant has been classified as Pathogenic. - |
X-linked lissencephaly with abnormal genitalia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Oct 02, 2014 | - - |
Corpus callosum agenesis-abnormal genitalia syndrome;C0796244:Intellectual disability, X-linked, with or without seizures, arx-related;C0796250:Partington syndrome;C1846171:X-linked lissencephaly with abnormal genitalia;C3463992:Developmental and epileptic encephalopathy, 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics Lab, CHRU Brest | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at